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ABSTRACT

Activation of the maternal immune system and resultant maternal cytokine
expression due to prenatal infection has been implicated as a significant contributor to
the pathology of neuropsychiatric and neurodevelopmental disorders such as
schizophrenia and Autism Spectrum Disorder (ASD). Increased maternal interleukin-6
(IL-6) expression, observed clinically and in animal models of prenatal infection, and
resultant activation of key signaling pathways, has been shown to be a biological
indicator of pathology, and a central component of the pathological mechanism.

In

animal models of prenatal infection and clinically in pregnancy disorders hallmarked by
immunological irregularities and increased IL-6 expression, inhibition of IL-6 has been
shown to reduce pathological symptoms both maternally and in the exposed offspring.
This study aims to demonstrate the ability of IL-6 expression, resulting from prenatal
infection, to induce neuropathological and behavioral outcomes that mirror clinical
observations seen in disorders such as ASD. More importantly, it shows how flavones
luteolin and diosmin, a subclass of the flavonoid family, through inhibition of IL-6
mediated activation of Signal Transducer and Activator of Transcription-3 (Stat3) can
reduce these pathologies both in vitro and in vivo.
Evidence suggests that flavonoids, a polyphenolic class of naturally occurring
plant secondary metabolites, are potent anti-inflammatory agents that can attenuate the
expression of cytokines such as IL-6, possibly through the modulation of tyrosine kinase
activity. They have been shown to have significant therapeutic potential in disorders
hallmarked by increased inflammation or disruptions in immune regulation, such as
vi

neurodegenerative disorders and certain cancers. Members such as diosmin have also
been shown to be safe during pregnancy, and are currently utilized in the treatment of
certain vascular disorders associated with pregnancy.
In vitro work undertaken in this study showed that co-administration of luteolin
with IL-6 in neural stem cells (NSC) was able to attenuate pathological outcomes
induced by IL-6 including aberrant proliferation, over expression of astroglial marker,
glial fibrillary acidic protein (GFAP) and changes in cellular morphology. In vivo studies
involving luteolin and diosmin further confirmed the therapeutic efficacy of these
compounds as similar attenuation of IL-6 mediated maternal and fetal pro-inflammatory
cytokine expression and abnormal behaviors in prenatally exposed offspring was
observed.

Mechanistically, these effects were mediated through inhibition of Stat3

activation although other pathways activated by IL-6 were modulated by flavone cotreatment. Flavonoid treatment during periods of prenatal infection may prove to be a
therapeutic intervention for the resultant pathological outcomes seen in offspring through
attenuation of the maternal and fetal immune response to infection as well as modulation
of signaling pathways in the fetal brain. These compounds may prove therapeutically
efficacious for the application in perinatal conditions hallmarked by increased
inflammation during pregnancy.

vii

CHAPTER 1

INTRODUCTION

1.1

Autism Spectrum Disorder (ASD)
It is estimated that approximately 13% of children in the U.S. ages 3 to 17 suffer

from at least one developmental disability that affects their behavior, memory, or
learning capability (Boulet et al., 2009, Boyle et al., 2011). The resulting impact on the
social, economic, educational, and health care delivery systems are significant, as the
economic cost of neurodevelopmental disorders in the US have been estimated to be
$81.5 to $167 billion per year (Boyle et al., 1994). Recently, Autism Spectrum Disorder
or autism (ASD) has gained significant focus as there has been an unprecedented
increase in the number of children diagnosed with the disorder, with an average increase
of 57% between 2002 and 2006 (Autism and Developmental Disabilities Monitoring
Network Surveillance Year 2006 Principal Investigators; Centers for Disease Control and
Prevention, 2009).

Although this increased prevalence has been attributed to

improvements in diagnostic criterion, it has nonetheless underscored the necessity for
increased research as an exact etiology for the disorder is still unknown. This increased
prevalence, coupled with the lack of a definitive etiological factor and therapeutic options
for patients and their families has fueled the urgency felt by parents, clinicians and
researchers to find a definitive etiology and therapeutic strategy for this disorder which
often carries a significant economic and emotional burden with lifetime care cost
estimated at $3.2 million per individual (Ganz, 2007)
1

The term autism was originally used by Eugen Bleuler to describe a cluster of
symptoms in schizophrenic individuals that included withdrawal or ‘self-isolation’. The
term would later be used by Leo Kanner in 1943 and Hans Asperger in 1944, to describe
a similar group of symptoms in children. Today however, the term autism is often used
synonymously for Autism Spectrum Disorder (ASD) to describe the cluster of symptoms
manifested in children displaying withdrawn or ‘isolated’ social behaviors (American
Psychiatric Association, 2000). The definition has now evolved to describe the group or
spectrum of behaviors characterized by impairments in reciprocal social interaction and
verbal and nonverbal communication skills compounded by symptoms of restrictive and
repetitive behaviors and/or stereotyped patterns of interest that are abnormal in intensity
or focus (American Psychiatric Association, 2000, Koenig and Scahill, 2001,
Zwaigenbaum et al., 2005). Included in this spectrum is ‘classical’ autism, which usually
involves social isolation, impaired verbal communication and stereotypical and repetitive
behaviors; Asperger syndrome, often described as a milder form of autism, lacking the
components of impaired verbal communication skills while retaining the intense
repetitive behaviors and difficulties in social interaction.

Also in the spectrum is

pervasive developmental disorder that usually encompasses disorders that cannot
otherwise be classified (American Psychiatric Association, 2000, Allen et al., 2001,
Koenig and Scahill, 2001, Zwaigenbaum et al., 2005).
Despite the advances in diagnostic criterion, the exact etiology of ASD has not
been identified, and although there have been significant advancements made in the
identification of key genes that are abnormally expressed within the autistic population a
single gene candidate has not been found (Andres, 2002, Belmonte and Bourgeron,
2006, Bernardet and Crusio, 2006, Chen et al., 2006, Campbell et al., 2008, Li et al.,
2008, Tetreault et al., 2009, Virkud et al., 2009, Kim et al., 2011). The genetic variation
and phenotypic heterogeneity within this population has led researchers to suggest
2

alternative hypotheses including the collective contributions of multiple genetic
disruptions as well as the synergistic interaction of environmental factors with genetic
polymorphisms or instabilities (Hornig et al., 1999, Fatemi et al., 2002, Fatemi et al.,
2005, Campbell et al., 2008, Fatemi et al., 2008b).
Prenatal infection has been one such ‘environmental factor’ with observations
from murine studies confirming the potential for prenatal infection, and more importantly
the resulting activation of the maternal immune system, to induce aberrant neurological
and behavioral outcomes in offspring reminiscent of the phenotypes observed clinically
in disorders such as schizophrenia and ASD (Fatemi et al., 2002, Shi et al., 2003,
Zuckerman et al., 2003, Fatemi et al., 2005, Smith et al., 2007, Fatemi et al., 2008b,
Winter et al., 2008, Ibi et al., 2009, Kirsten et al., 2010, Ghiani et al., 2011). Similarly,
epidemiological data and clinical cases of prenatal infection have supported the potential
for this event to precipitate adverse neurological outcomes with an increased incidence
of preterm births and cerebral palsy, a neurological disorder involving impairments in
motor and cognitive function, visual and auditory perception observed in prenatally
exposed infants.

Fetal Inflammatory Response Syndrome (FIRS), a disorder

characterized by systemic inflammation and uncharacteristically high levels of plasma IL6 in the affected newborn as well as increased circulating IL-6 in the placental and
umbilical cord plasma is also seen in infants exposed prenatally to intra-amniotic
bacterial infection or viral infection and often results in preterm births, and adverse
neurological outcomes such as cerebral palsy (Gomez et al., 1998, Chaiworapongsa et
al., 2002, Gotsch et al., 2007).

1.2

Prenatal infection, Cytokines and Pregnancy
Although the exact mechanism may not be fully understood, the activation of the

maternal immune system following prenatal infection, and specifically the increases in
3

pro-inflammatory cytokine expression has been shown to be integral in precipitating the
adverse neurological and behavioral outcomes observed in prenatally exposed offspring
(Ashdown et al., 2006, Fortier et al., 2007, Jonakait, 2007, Ghiani et al., 2011).
Cytokines, small signaling molecules secreted by cells to mediate intercellular
communication, have long been shown to play a vital role in immune regulation,
particularly in the progression of inflammatory responses to stimuli including pathogenic
insults (Bromberg and Wang, 2009, Sweeney, 2011, Liu et al., 2012). Their role extends
beyond their pathological activities however as they have been shown to be equally
important in physiological events particularly the development and function of various
cellular populations. In the immune system, cytokines regulate the differentiation and
mobilization of T-cell populations, an important event in response to pathogenic stimuli
as well as during pregnancy (Makhseed et al., 2000, Schluns and Lefrancois, 2003,
Norton et al., 2010, Robertson et al., 2010, Zhu and Paul, 2010, Zwirner and Domaica,
2010, Morrison et al., 2011, Tower et al., 2011). It is this regulatory role that may begin
to explain the implications of maternal immune activation during prenatal infection in
precipitating adverse perinatal outcomes as disruptions in cytokine expression have
been observed in adverse perinatal outcomes (Tosun et al., 2010, Vitoratos et al., 2010,
Hsiao and Patterson, 2011, Wang et al., 2011).
During pregnancy, cytokines serve as regulators at the maternal-fetal immune
interface, preventing maternal rejection of the fetus by maintaining the balance between
immune-suppressive regulatory T cells (T-regs) and cytotoxic T cells (Th1, Th17)
(Piccinni and Romagnani, 1996, Makhseed et al., 2000, Piccinni et al., 2000, Piccinni,
2002, Kanellopoulos-Langevin et al., 2003, Aluvihare et al., 2004, Poole and Claman,
2004, Aluvihare et al., 2005, Petroff, 2005, Piccinni, 2005, 2010, Saito et al., 2010,
Shima et al., 2010). Murine models and human clinical studies have confirmed this
interplay, with observations of changes in cytokine expression and a shift in the
4

differentiation of naïve T cells toward a T-regulatory phenotype during the periimplantation period (Zenclussen, 2006b, Zenclussen et al., 2006, Guerin et al., 2009,
Ernerudh et al., 2011, Leigh R. Guerin, 2011). Additionally, adverse pregnancy
outcomes such as recurrent miscarriages, preeclampsia, and instances of restricted fetal
growth have been attributed to placental dysfunction, specifically the inability of the
placenta to fully maintain an immunological balance as increased cytotoxic T-cells,
particularly Th17 cells, have been observed in these disorders along with increased
levels of pro-inflammatory cytokines particularly IL6 (Makhseed et al., 2000, Zenclussen,
2006b, a, Piccinni, 2007, Lai et al., 2010, Laresgoiti-Servitje et al., 2010, Saito et al.,
2010, Tosun et al., 2010, Jin et al., 2011, Liu et al., 2011a, Liu et al., 2011b, Saini et al.,
2011, Raghupathy et al., 2012).

1.3

Cytokines in neurodevelopment
The activity of cytokines, both physiologically and pathologically have also been

extensively described beyond their role in the peripheral immune system as they
participate in the central nervous system (CNS) as key mediators in neurodegenerative
disorders and other instances characterized by neuroinflammation and also in normal
CNS development and function (Ajmone-Cat et al., Burns et al., 1993, Pousset, 1994a,
Zhao and Schwartz, 1998, Balschun et al., 2004, Bauer et al., 2007, Deverman and
Patterson, 2009, Jellinger, 2010, Appel et al., 2011, Matousek et al., 2011). During CNS
development, cytokines are present and functional in the fetal brain, with receptors
identified on both neuronal and glial cells (Pousset, 1994b, Rothwell et al., 1996, Dame
and Juul, 2000). They exert their regulatory effects propagating permissive or inhibitory
signals to coordinate the birth and terminal differentiation of neuronal and glial cell
populations, their migration and positioning in the brain and the formation and
maintenance of functional synapses (Bauer et al., 2007, Deverman and Patterson,
5

2009).

This regulatory role may explain the ability for pathological expression of

cytokines such as IL-6, during prenatal infection to produce disruptions in cellular events
including changes in migratory patterns and synaptic function that may manifest in the
adverse neurological symptoms observed clinically in disorders such as ASD.

1.4

Prenatal infection and implications for neurodevelopmental disorders:
Evidence from fetal inflammatory response syndrome (FIRS)
The idea of an ‘environmental insult’ precipitating neurodevelopmental disorders

is not a novel hypothesis as several compounds, including toxins and heavy metals,
have been shown to cause neurological and congenital abnormalities in children
exposed prenatally (Silbergeld and Patrick, 2005, Wigle et al., 2007, Sutton et al., 2010,
Schoeters et al., 2011). The link between prenatal infection and disruptions in fetal
development is also not a novel idea. Several researchers have observed correlations
between maternal infections, pre-term births and neurological disorders such as cerebral
palsy, ASD and schizophrenia in these prenatally exposed infants (Barak et al., 1999,
Jacobsson and Hagberg, 2004, Atladottir et al., 2010, Kinney et al., 2010, Monji et al.,
2011). FIRS is one example of how prenatal infection can lead to adverse pregnancy
outcomes and compromise fetal development.

FIRS is observed in fetuses and

newborn infants exposed to infections in utero and is characterized by systemic
inflammation including abnormally high levels of IL-6 and has been correlated with an
increased occurrence of neurological disorders such as cerebral palsy.

Although

described in the context of fetal pathology, FIRS is precipitated by maternal infection,
specifically, bacterial infections of the amniotic fluid, placenta, uterus or fetal
membranes, although viral infections can induce similar pathologies (Fahey, 2008).
Known as intra-amniotic infections, they elicit maternal and fetal immunological
responses including cytokine release, leukocyte migration and rupture of the fetal
6

membranes. It is this inflammatory response that is thought to induce maternal and fetal
pathological outcomes including preterm birth and neurological disruptions (Gomez et
al., 1998, Romero et al., 2000, Romero et al., 2003, Jacobsson and Hagberg, 2004,
Gotsch et al., 2007, Fahey, 2008, Fuksman and Mazzitelli, 2009). Additionally, murine
models of prenatal infection have also mirrored clinical findings in FIRS including
observations of increased maternal cytokines such as IL-6 which appear to precipitate
the adverse behaviors and neuropathologies observed in exposed offspring.

1.5

Prenatal infection and neurodevelopmental disorders– IL-6 as a central
mechanism and therapeutic target
Indeed findings from FIRS, murine models of prenatal infection and preeclampsia

have supported a role maternal and potentially fetal inflammatory response and cytokine
expression, particularly IL-6, in the adverse perinatal outcomes precipitated by prenatal
infection including the behavioral abnormalities in exposed offspring (Boksa, 2004,
Zenclussen, 2006a). These models have shown that IL-6 is a key component of the
pathological mechanism, with its inhibition attenuating pathological symptoms (Campbell
et al., 1993, Smith et al., 2007, Tosun et al., 2010, Covey et al., 2011, Wang et al.,
2011). Although the exact mechanism by which IL-6 contributes to these pathologies
may not be fully understood, the physiological role of cytokines and in this instance IL-6,
during CNS development and in immune regulation may help elucidate how its
disruption following prenatal infection can lead to pathological outcomes.
A member of the gp130 family of cytokines, IL-6 and its counterparts propagate
their regulatory and pathological effects through the activation of a common signaling
component, Signal Transducers and Activators of Transcription (Stat3) (Heinrich et al.,
1998, Deverman and Patterson, 2009, Islam et al., 2009). It is this common pathway
that may allow pathological expression of IL-6 during instances of prenatal infection to

7

disrupt placental function and developmental events mediated by Stat3 activity. The
differentiation of cytotoxic T-cell populations for example has been shown to be a Stat3
dependent highly influenced by IL-6 expression.

T-cells play a critical role during

pregnancy and clinical studies have suggested that T-cell disturbances may play an
important role in pregnancy disorders (Kimura and Kishimoto, 2010, Saini et al., 2011).
Similarly, the differentiation of astroglial cells from neural stem cell populations has also
been shown to be Stat3 dependent and disruptions in this population have been
observed in neurological disorders associated with prenatal infection such as ASD
(Brunello et al., 2000, He et al., 2005, Islam et al., 2009, Bilbo, 2011, Sicca et al., 2011).
Observations that the inhibition of IL-6 may attenuate pathological symptoms
arising from prenatal infection have provided a potential mechanism for understanding
the role of IL-6 in these pathologies as well as a new strategy that can be utilized to
develop therapeutic alternatives. In preeclampsia for example, a disorder in pregnancy
characterized by the sudden onset of hypertension and protein in the urine after the 20th
week, increased levels of IL6 has been identified as a key indicator of disease pathology
as well as a therapeutic target with its inhibition attenuating hypertensive symptoms and
other associated pathologies (Lockwood et al., 2008, Lamarca et al., 2011, Zhou et al.,
2011). Similarly in murine models of prenatal infection, increased levels of IL-6 have
been observed following infection and have been shown to play a major role in the
neuropathologies and abnormal behaviors seen in the exposed offspring while the
inhibition of IL-6, and Stat3 activity have been shown to counteract these pathologies
(Smith et al., 2007).

1.6

Therapeutic potential of Flavonoids – ‘Flavones’
Recently flavonoids, a class of polyphenolic plant metabolites have gained

significant attention in cancer and inflammation research because of their therapeutic
8

potential, acting as immune modulators in various pathological disorders (Hirano et al.,
2004, Kawai et al., 2007, Seelinger et al., 2008, Geraets et al., 2009). Grouped on the
basis of their structural attributes, flavonoids have properties ranging from antiinflammatory to anti-carcinogenic attenuating immune reactions in inflammatory cells
and aberrant proliferation in cancer cells largely through the modulation of tyrosine
kinase activity. Luteolin, a member of the flavone class of flavonoids, and found in
chamomile and celery among other plants, is known to have significant anti-inflammatory
and anti-tumor potential attenuating cytokine production in immune cell populations,
while displaying pro-apoptotic properties in tumor cell lines and murine models of cancer
(Rezai-Zadeh et al., 2008, Seelinger et al., 2008, Kang et al., 2011). Luteolin, like many
of the other flavonoids has also been shown to be blood-brain barrier permeable, a
characteristic that makes it an appealing therapeutic strategy for the neurological
disorders precipitated by prenatal infection, when coupled with its anti-inflammatory
potential (Jang et al., 2008). Diosmin, a semisynthetic flavonoid derivative, has also
been shown to have similar therapeutic potential being utilized for the treatment of
vascular disorders. This research outlines how flavonoids luteolin, and diosmin, can
inhibit the adverse effects of IL6, including the disruptions in maternal immunity following
prenatal infection and the neuropathological and behavioral abnormalities observed in
the exposed offspring, potentially serving as a useful therapeutic intervention during
instances of prenatal infection and immune dysfunction during pregnancy.

9

CHAPTER 2
MATERIALS AND METHODS

2.1

Reagents
Luteolin (>95% purity by HPLC) was generously donated by Pharma Science

Nutrients (Ocala, FL, USA). Diosmin (>90% purity by HPLC) was purchased from Axxor
(San Diego, CA, USA). Antibodies against Jak2, phospho-Jak2, Stat3, phospho-Stat3,
phospho-PI3K, phospho-Akt, Akt, phosphor-ERK1/2 (p44/42), vimentin and nestin were
obtained from Cell Signaling Technology (Danvers, MA, USA).

Antibodies against

GFAP, Doublecortin (DCX), and Beta-tubulin were obtained from Abcam (Cambridge,
MA, USA). Murine recombinant IL-6 (mIL-6 or IL-6) and cytokine ELISA kits were
purchased from eBioscience (San Diego, CA, USA). BCA protein assay kit was
purchased from Pierce Biotechnology (Rockford, IL, USA) and Cyquant Cell Proliferation
assay kit from Invitrogen (Grand Island, NY).

2.2

Cell culture

2.2.1

Murine derived Primary neural stem cells (NSC)
Cerebral cortices isolated from C57BL/6 mouse embryos, 14 days in utero were

obtained from Stem Cell Technologies. In preparation for culture, neurospheres were
mechanically dissociated, centrifuged at 90 x g for 5 minutes, and resuspended and
maintained in 1:1 Dulbecco’s Modified Eagle Medium: Nutrient Mixture F12 (DMEM/F12)
supplemented with 2% B27 serum free supplement, 5µg/µl fibroblast growth factor (FGF,
Sigma-Aldrich, St. Louis, MO, USA) and 10µg/ml epidermal growth factor (EGF, Sigma10

Aldrich, St. Louis, MO, USA). Prior to treatment, cells were plated in 96 well collagencoated culture plates at a density of 2x104 cells per well, 8 well collagen coated, poly-dlysine treated culture plates at a density of 2.5 x 105 cells per well, or 6 well collagencoated culture plates at a density of 1 x 106.

All cultures were maintained in the

previously described media formulation prior to treatment unless otherwise indicated and
incubated at 37°C in 10% CO2 before and during treat ment.

2.2.2

Murine immortalized neuroblastoma cells (N2a)
N2a (murine neuroblastoma) cells, purchased from the American Type Culture

Collection (ATCC, Manassas, VA) were maintained in complete DMEM supplemented
with 10% fetal calf serum. Cells were plated in 96 well collagen-coated culture plates at
a density of 2x104 cells per well, or 6 well collagen-coated culture plates at a density of
1x106 cells per well. All cultures were maintained in the previously described media
formulation prior to treatment and incubated at 37°C in 10% CO2 before and during
treatment.

2.2.3

Murine derived primary splenocytes
Spleens isolated from female C57BL/6 mice were dissected and mechanically

dissociated to obtain a single cell suspension. Cells were re-suspended and washed in
complete Roswell Park Memorial Institute 1640 (RPMI 1640) containing 10% serum,
centrifuged at 400 x g for 5 minutes, then washed in PBS, followed by centrifugation at
400 x g for 5 minutes. To remove red blood cells, splenocytes were resuspended in ACK
lysis buffer and incubated per manufacturer’s instructions. Cells were washed 3 times in
PBS, resuspended in RPMI 1640 containing 10% serum, and incubated at 37ºC, 5%
CO2 prior to treatment.
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2.2.4

Treatments
For proliferation experiments, after overnight incubation cells incubated in 96 well

plates were treated with various concentrations of murine recombinant IL-6 (0, 3.125,
6.25, 12.5, 25, 50ng/mL) or cotreated with 50ng/mL murine recombinant IL-6 and
various concentrations of luteolin (0, 1.25, 2.5, 5, 10, 20 µM) for 24 hours. For western
blot analysis, cells were treated with 50 ng/mL murine recombinant IL-6 for a range of
time points (0, 15, 30, 45, 60 or 75 minutes) or 50 ng/mL murine recombinant IL-6 in the
presence of various concentrations of luteolin (0, 1.25, 2.5, 5, 10, 20 µM) for 30 minutes.
For immunocytochemistry, cells were treated with 50 ng/mL murine recombinant IL-6 in
the presence or absence of 20uM luteolin.
For assays performed under differentiated conditions, neural stem cells were
incubated in neurobasal media supplemented with 2% B27 while neuroblastoma cells
were incubated in neurobasal media supplemented with 3 mM dibuturyl cAMP. Reagent
concentrations and length of treatment maintained. All experiments were performed in
triplicate.

2.3

Mice

2.3.1

Housing and maintenance
C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, MA) and

maintained in an animal facility of the University of South Florida (USF). All animals
were given ad libitum access to food and water and were maintained on a 12-hour
light/dark schedule. All subsequent experiments were performed in compliance with
protocols approved by the USF Institutional Animal Care and Use Committee.

2.3.2

Treatments
Pregnant mice were injected intraperitoneally with IL6 (5ug/mouse),
12

lipopolysaccharide (LPS) (50ug/kg), or phosphate buffered saline (PBS) as control on
embryonic day 12.5 (E12.5) and divided equally among three separate groups. The first
group was co-injected with Luteolin (20mg/kg), the second group was placed on diosmin
supplemented diets (10 mg/kg/day, 0.005% in NIH31 chow) and the third group coinjected with the STAT3 inhibitor S31-201. A minimum of four pregnant females per
treatment were utilized for all experiments.

2.4

Lysate and homogenate preparation
Cultured cells were lysed in ice-cold lysis buffer (20 mM Tris, pH 7.5, 150 mM

NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium pyrophosphate, 1
mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 1 mM PMSF) for 5 minutes
followed by scraping. Lysates were collected, briefly vortexed and centrifuged at 14,000
x g for 15 minutes at 4º C.
Mouse brains and spleens were isolated under sterile conditions on ice and
placed in ice-cold lysis buffer. Tissues were sonicated on ice for approximately 3
minutes, allowed to stand for 15 minutes at 4°C, and then centrifuged at 15,000 x g for
15 minutes at 4°C. Total protein content in cell lysates a nd tissue homogenates were
estimated using the bicinchoninic acid assay (BCA protein assay, Pierce Biotechnology)
per manufactures instructions and normalized.

2.5

Western Blot Analysis
Aliquots corresponding to 100ug of total protein were electrophoretically

separated using 12% SDS gels. Electrophoresed proteins were then transferred to
nitrocellulose membranes (Bio-Rad, Richmond, CA), washed in Tris buffered saline with
0.1% Tween-20 (TBS/T), and blocked for one hour at ambient temperature in TBS/T
containing 5% (w/v) non-fat dry milk.

After blocking, membranes were hybridized
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overnight at 4°C with various primary antibodies. Me mbranes were then washed three
times for five minutes each in TBS/T and incubated for one hour at ambient temperature
with

the

appropriate

Biotechnology).

HRP-conjugated

secondary

antibody

(1:1,000,

Pierce

Primary antibodies were diluted in TBS/T containing 5% BSA and

secondary antibodies in TBS containing 5% (w/v) of non-fat dry milk.
developed using the luminol reagent (Pierce Biotechnology).

Blots were

Densitometric analysis

was conducted using a FluorS Multiimager with Quantity One™ software (BioRad,
Hercules, CA). For phospho-Stat3 detection, membranes were probed with a phosphoSer727 and phosphor-Tyr705 Stat3 antibody (1:1,000) and stripped with stripping
solution and then re-probed with antibody that recognizes total Stat3 (1:1,000). Similarly
for phospho-Jak2 detection, phosphor-Akt, and phosphor-Erk(1/2) membranes were
probed with appropriated phosphor antibodies (1:1,000) and stripped and re-probed for
corresponding total antibody (1:1,000).

2.6

ELISA Cytokine Analysis
Mouse brain and spleen homogenates were prepared as described above and

used at a dilution of 1:10 in cell lysis buffer for these assays.

Tissue-solublized

cytokines were quantified using commercially available ELISAs that allow for detection of
IL-1β, IL-6 and TNF-α.

Cytokine detection was carried out according to the

manufacturer’s instruction. Data was represented as pg of cytokine/mg total cellular
protein for each cytokine.

2.7

Proliferation Assay
Cells plated in 96 well plates were treated as described in cell culture treatments

subsection.

Following treatment proliferation was quantified using the Cyquant

proliferation assay per manufactures instructions.
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2.8

Tissue Section Preparation
Postnatal day 0 mice were anesthetized with in an ice bath. Brains being utilized

for immunofluorescence and immunohistochemistry were immediately isolated and
incubated in paraformaldehyde at 4ºC for 24hrs.

Brains were then sequentially

transferred to increasing concentrations of sucrose for 72hrs up to a final concentration
of 30% sucrose. Brains were then cyrosectioned at 30um and placed in freezing media
until staining.

2.9

Immunofluoresence Analysis
Cells cultured in eight well culture slides were treated as described outlined in

chapter 3.

After treatment, cultured cells were washed, and then fixed with 4%

paraformaldehyde in phosphate-buffered saline (PBS; 0.1 M, pH 7.4) for 30 min at room
temperature. Cells were then washed in PBS three times for five minutes each then
permeabilized with 0.05% Triton X-100 (Sigma), washed with PBS three times for five
minutes each, then blocked with 5% horse serum in dilution buffer (0.05% Triton X-100)
for one hour. Cells were then incubated overnight at 4ºC with various primary antibodies
diluted in blocking buffer. After overnight incubation, cells were washed three times for
five minutes each in PBS and incubated for 45 minutes at room temperature with the
appropriate HRP-conjugated secondary antibody. After incubation, cells were washed
three times for five minutes in PBS, mounted using vector shield with DAPI, and
analyzed using confocal microscopy.
Brain sections were washed three times for five minutes then blocked in 5%
horse serum for one hour.

Sections were then washed and incubated in primary

antibody overnight at 4ºC. After incubation, sections were washed and incubated in
secondary antibody, for 45 minutes.

Cells were then washed three times for five

minutes, mounted onto slides and cover slipped with DAPI mounting media.
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2.10

Immunohistochemistry
Brains being utilized for immunohistochemistry studies were prepared as

mentioned in immunofluorescence procedure. After incubation in secondary antibody,
sections were incubated in VectaStain Elite ABC reagent (Vector Laboratories,
Burlingame, CA) coupled with diaminobenzidine (DAB) substrate. Stained sections were
mounted onto coverslips, air dried, and washed in distilled deionized water two times for
five minutes. Sections were then rinsed through three rapid changes of ethanol, cleared
through three xylene washes and cover slipped with permount. Sections were visualized
using bright field Olympus BX-51 Sections microscope.

2.11

Behavioral analysis

2.11.1 Open Field
General locomotor activity of mice was assessed using the open field test. Mice
were placed in a 50 x 50cm white Plexiglas box brightly lit by fluorescent room lighting
and six 60 W incandescent bulbs approximately 1.5 m above the box. Activity was
recorded by a ceiling-mounted video camera and analyzed from digital video files either
by the automated tracking capabilities of Ethovision or counted using the behavior
tracker (version 1.5, www.behaviortracker.com), a software-based event-recorder. The
total distance moved and numbers of entries into the center of the arena (central 17 cm
square) were determined in a 10 minute session. General activity levels were evaluated
by measurements of horizontal activity and vertical activity. Anxiety was also assessed
by examining the ratio of center distance traveled to total distance traveled. As the
natural tendency of the mice is to avoid open areas, animals that show greater tendency
to explore in the center of the field show a lower tendency for anxiety, or the reverse
situation can indicate a higher anxiety level.
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2.11.2 Social Interaction
To assess social interaction, treatment mice were allowed to interact with a
stranger mouse and the level of interaction, including sniffing and other investigative
behaviors was measured. The testing apparatus consisted of a 60 x 40 cm Plexiglas
box divided into three chambers.

Mice were be able to move between chambers

through a small opening (6 x 6 cm) in the dividers. Plastic cylinders in each of the two
side chambers contained the probe mice, and numerous 1cm holes in the cylinders
enabled test and probe mice to contact each other. Test mice were placed in the center
chamber, with an overhead camera recording their movements. Mice were allowed five
minutes of exploration time in the box, after which an unfamiliar, same-sex probe mouse
from the same experimental group was placed in one of two restraining cylinders
(Radyushkin et al., 2009). The Ethovision software (Noldus, Leesburg, VA) program
measured time spent in each of the three chambers, and social preference was defined
as follows: (% time spent in the social chamber) - (% time spent in the opposite
chamber).

2.12

Statistical analysis
All data were normally distributed; therefore, in instances of single mean

comparisons, Levene's test for equality of variances followed by t-test for independent
samples was used to assess significance. In instances of multiple mean comparisons,
analysis of variance (ANOVA) was used, followed by post-hoc comparison using
Bonferroni's method. Alpha levels were set at 0.05 for all analyses unless otherwise
indicated. The STATistical package for the social sciences release 10.0.5 (SPSS Inc.,
Chicago, IL, USA) was used for all data analysis.
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CHAPTER 3

LUTEOLIN ATTENUATES IL-6 MEDIATED CHANGES IN NEURAL STEM CELLS VIA
INHIBITION OF STAT3 ACTIVITY: IMPLICATIONS FOR PRENATAL INFECTION

3.1

Regulation of central nervous system (CNS) development

3.1.1

Role of gp130 cytokines and Stat3
It has been established that CNS development is an inherently vulnerable period

with subtle changes in the immediate cellular environment leading to disruptions in the
morphology and function of neural populations that can precipitate adverse neurological
outcomes. This vulnerability has been attributed to the high degree of regulation
necessary during this period to coordinate the actions of the milieu of morphogenic
factors, including cytokines. Cytokines are important in the development of the CNS as
they play a key role in the fate specification and terminal differentiation of neuronal and
glial populations, the migration of neurons to the final position in the CNS, the formation
and maintenance of functional synapses, the sequential manner in which these
cytokines are expressed and the temporal nature in which these events occur
(Pekkanen-Mattila et al., 2010).
During early embryogenesis for example, the emergence of the neuroectoderm
from embryonic stem cells signals the formation of the CNS and coincides with the
expression of transcription factors such as sex determining region Y – box1 (Sox1).
Sox1 is implicated in directing the fate specification and expansion of this multipotent
cellular population as well as ensuring its maintenance through active proliferation and
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the inhibition of further differentiation (Suter et al., 2009, Elkouris et al., 2011). By
contrast, paired box 6 (Pax6), expressed after Sox1, induces neuroectoderm to
differentiate into radial glial and subsequently neuronal cells (Warren et al., 1999, Mo
and Zecevic, 2008, Sansom et al., 2009). Similarly, the transition from neurogenesis to
gliogenesis is regulated by the sequential expression of pro-neuronal and pro-astroglial
cytokines and morphogenic factors in addition to cell intrinsic mechanisms that act on
multi-potent radial glial populations. At the onset of neurogenesis, precursor cell pools
differentiate preferentially into neuronal cells under the availability of pro-neuronal
cytokines such as neurogenin, while gliogenic genes are repressed through methylation,
and transcription factors inhibited through protein modification (Deverman and
Patterson, 2009). These inhibitory mechanisms are coupled with the reduced availability
of pro-glial cytokines, which altogether support the differentiation of neuronal cells while
restricting the astroglial differentiation. As neurogenesis progresses, the accumulation
of neuronal proteins, such as cardiotrophin-1 (CT-1), a gp130 cytokine expressed by
newly differentiated neurons, induces astroglial differentiation through activation of the
Stat3 (Sauvageot and Stiles, 2002, Barnabe-Heider et al., 2005).

3.1.2

Stat 3 in neurodevelopmental disorders
Maternal immune dysregulation, following prenatal infection and resultant

expression of cytokines such as IL6 provide a unique opportunity for neuropathological
consequences due to the disruption of the Stat3 pathway, and the developmental events
it regulates. Murine models of Stat3 mutations have highlighted the role of Stat3 in
neuropathological outcomes as these models have yielded observations ranging from
disruptions in synaptic transmission, neuronal migration, and abnormal neuronal and
glial morphologies to embryonic lethality depending on the extent of the mutation
(Campbell et al., 1993, Brunello et al., 2000). Particularly, disruptions in synaptic
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transmission, potentially due to neuronal overgrowth or astroglial abnormalities have
been thought to precipitate the behavioral pathologies in animals possessing these
mutations. Similar disruptions in neuronal populations have also been implicated in the
behavioral abnormalities observed clinically in disorders such as ASD (Campbell et al.,
1993, Brunello et al., 2000).
The ability of IL6 mediated Stat3 disruptions to alter astroglial differentiation and
function may particularly suggest an indirect mechanism of precipitating these
pathologies.

During development, expression and subsequent binding of gp130

cytokines such as CT-1 to the gp130-Janus tyrosine kinase-2/Signal Transducer and
Activator of Transcription-3 (Jak2/Stat3) receptor complex triggers a series of
phosphorylation including the activation of Stat3, its entry into the nucleus and
subsequent transcription of astroglial genes such as GFAP (Akira, 1997, Heinrich et al.,
1998, Deverman and Patterson, 2009). Astrocytes are important constituents of the
CNS providing migratory scaffolding for neurons during development and the later
regulating synaptic transmission through the release of neuroactive compounds,
clearance of neurotransmitters from the synaptic cleft, or direct communication with
neurons (Brunello et al., 2000). Disruption of astroglial function have been shown to
have deleterious effects, and has been implicated in disorders such as epilepsy, a
condition found to be a common comorbidity with ASD in a subset of this population
(Dutuit et al., 2000, Brenner et al., 2001, Laurence and Fatemi, 2005, Vargas et al.,
2005, Jabs et al., 2008). Astrocyte disruptions have also been directly implicated in the
pathology of ASD with disruptions in several astroglial markers including GFAP elevated
in the brains of autistic individuals, a potential fetal inflammatory response to prenatal
infection (Fatemi et al., 2008a). Stat3 mediated regulation of astrocyte development and
function is therefore important in regulating CNS function.
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3.2

Results

3.2.1

Luteolin attenuates IL-6 mediated neuronal Jak2/Stat3 phosphorylation
The effects of IL-6 has been shown to be a largely Stat3 dependent event.

During CNS development, the maintenance of stem cell populations through active
proliferation and the initiation of gliogenesis in neural stem cells have also been shown
to be mediated by activation of Stat3. To determine the efficacy of luteolin in attenuating
IL-6/Stat3 mediated activation and resultant pathologies, Jak2/Stat3 phosphorylation
was measured in murine neuroblastoma (Neuro-2a) cells.

IL-6, like other gp130

cytokines bind to their respective gp130 receptor complex to activate Stat3 through a
series of phosphorylation events beginning with the phosphorylation of Jak2, followed by
the phosphorylation, dimerization and nuclear entry of Stat3. Once in the nucleus, Stat3
binds target DNA sequences to initiate the transcription of Stat3 dependent genes such
as glial fibrillary acidic protein (GFAP) at the onset of gliogenesis. To examine IL-6
mediated activation of the Jak2/Stat3 pathway, Neuro-2a cells were treated with 50
ng/mL of murine recombinant IL-6 (mIL-6) in a time dependent manner. Alternatively,
cells were also co-treated with mIL-6 and increasing concentration of luteolin (0µM 20µM) for 30 minutes. Western blot analysis of cell lysates showed that IL-6 treatment
induced a time dependent increase in Jak2 phosphorylation beginning at 30 minutes and
continuing until 75 minutes, when the timed analysis was concluded (fig. 3.1a). When
cell lysates of luteolin co-treated cells were analyzed, there was significant inhibition of
Jak2 phosphorylation observed beginning at 10µM.
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a

**

b

**

Figure 3.1a-b
Luteolin attenuated IL-6 mediated Jak2 phosphorylation in neuroblastoma cells.
Densitometric analysis of the ratio of phospho Jak2 to total Jak2, and one way ANOVA
showed mIL-6 treatment significantly induced Jak2 phosphorylation in a time dependent
manner beginning at 30 minutes (**p<0.005) (a). Luteolin co-treatment significantly
inhibited the effects of IL-6, attenuating IL-6 mediated phosphorylation beginning at
10µM (**p<0.01) (b).
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Stat3 phosphorylation in Neuro-2a cells was analyzed next.

IL-6 treatment

resulted in a significant increase in Stat3 phosphorylation at residue Ser727 beginning at
30 minutes, and remaining significant until the end of treatment at 75 minutes. Luteolin
co-treatment significantly inhibited IL-6 mediated Stat3 phosphorylation beginning at
10µM.
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Figure 3.2a-b
Luteolin attenuated IL-6 mediated Stat3 phosphorylation in neuroblastoma cells.
Densitometric analysis of the ratio of phosphor Stat3 to total Stat3, and one way ANOVA
showed mIL-6 treatment significantly induced Stat3 phosphorylation in a time dependent
manner beginning at 30 minutes (**p<0.005) (a). Luteolin co-treatment significantly
attenuated this phosphorylation beginning at 10 µM (*p<0.01, **p<0.001) (b). Similar
results were obtained using antibody specifically against phospho-Star3 (Tyr705).
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3.2.2

Luteolin attenuates IL-6 mediated effects in neural stem cells through
inhibition of the Jak2/Stat3 phosphorylation
Although neuroblastoma cells are often utilized as an in vitro model to examine

CNS pathologies the effects of IL-6 and the therapeutic efficacy of luteolin was further
examined in neural stem cells isolated from embryonic mouse cortices, to closer
approximate the in vivo environment during CNS development. Phosphorylation of Jak2
was examined following mIL-6 treatment or luteolin and mIL-6 co-treatment. In cultures
treated with mIL-6 Jak2 phosphorylation was significantly increased at 15 minutes post
treatment, reaching a maximal intensity at 45 minutes (fig. 3.3a).

When Stat3

phosphorylation was examined, there was a similar phosphorylation pattern observed
with a significant increase in phosphorylation in response to IL-6 treatment at residue
Tyr705.

Phosphorylation at residue Ser727 was significant at 45 minutes (fig. 3.3c).

Luteolin co-treatment significantly inhibited IL-6 mediated phosphorylation of Jak2 and
Stat3 at both residues at 20µM (fig. 3.3b&d).
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a

b

Figure 3.3a-b
Luteolin attenuated IL-6 mediated phosphorylation of Jak2/Stat3 in neural stem cells.
Densitometric analysis showed mIL-6 treatment significantly induced Jak2
phosphorylation in a time dependent manner beginning at 15 minutes, remaining
significant until 45 minutes (a). This phosphorylation was attenuated by luteolin cotreatment (b). (*=p<0.01)
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Figure 3.3c-d
Densitometric analysis showed mIL-6 treatment significantly induced Stat3
phosphorylation in a time dependent manner beginning at 15 minutes, remaining
significant until 30 minutes (c). This phosphorylation was attenuated by luteolin cotreatment (d). (*=p<0.01)
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3.2.3

Luteolin attenuates IL-6 mediated activation of Protein kinase B (Akt) and
Migtogen activated protein kinase (Erk1/Erk2) pathways in neural stem
cells
Although Stat3 has been shown to be a key transcription factor and regulatory

agent during neurodevelopment, other pathways, such as protein kinase B, also known
as Akt, and mitogen activated protein kinase or Erk1/Erk2 have been shown to play
important roles. These pathways have also been shown to interact and regulate the
activity of Stat3 and are responsive to IL-6 treatment. Erk1/Erk2 for example in addition
to regulating neuronal differentiation has been shown to regulate Stat3 activity at Ser727,
through phosphorylation.

Although the exact purpose of this event is not fully

understood, it has been hypothesized that Erk1/Erk2 mediated serine phosphorylation
regulates Stat3 homodimerization, while other groups have hypothesized a role in
regulating transcriptional activity and DNA binding (Wen et al., 1995, Zhang et al., 1995,
Chung et al., 1997). The effects of luteolin on these pathways were examined as well.
In neural stem cells cultures treated with IL-6 there were significant increases in Akt
phosphorylation and Erk1/Erk2 phosphorylation at which was inhibited by luteolin cotreatment. Although it is not clear how activation of these pathways, or inhibition by
luteolin for that matter impacts the pathological effects of mIL-6, or the ability of luteolin
to attenuate these events, their interactions with Stat3, and role in development suggest
that they may play some role in regulation.
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Figure 3.4
Luteolin attenuated IL-6 mediated phosphorylation of Protein kinase B (Akt) in neural
stem cells. Densitometric analysis showed mIL-6 treatment significantly induced Akt
phosphorylation in a time dependent manner beginning at 15 minutes, remaining
significant until 30 minutes (a). This phosphorylation was attenuated by luteolin cotreatment (b). (*=p<0.01)
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Figure 3.5a-b
Luteolin attenuated IL-6 mediated phosphorylation of Mitogen activated protein kinase
(Erk1/Erk2) in neural stem cells. Densitometric analysis showed mIL-6 treatment
significantly induced Stat3 phosphorylation in a time dependent manner beginning at 15
minutes, remaining significant until 30 minutes (a). This phosphorylation was attenuated
by luteolin cotreatment (b). (*=p<0.01)
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3.2.4

Luteolin attenuates IL-6 induced proliferation in neuroblastoma cells
Increases in the number of neuronal cells in certain regions of the brain have

been one pathological feature described in ASD, and may be attributed to disruptions in
the proliferative or apoptotic mechanisms during key phases of neurodevelopment.
Activation of the Stat3 pathway by gp130 cytokines has been shown to be a potent
inducer of proliferation, with dysregulation of Stat3 being an important mechanism in
certain cancers.

The potential of IL-6 to induce proliferation in neuronal cells was

examined in Neuro-2a cells. Undifferentiated and differentiated Neuro-2a were treated
with murine recombinant IL-6 (mIL-6) for 24hours and proliferation measured as a
function of fluorescent intensity of labeled nucleic acid residues.

IL-6 treatment

significantly increased proliferation in undifferentiated Neuro-2a cells at even minimal
concentrations of 1.625ng/mL, with proliferation peaking at 12.5ng/mL. Although this
proliferative effect declined with increasing concentration, 25 – 100ng/mL, it remained
significant in comparison to control levels (fig. 3.6a). By contrast, in differentiated N2a
cells, the effects of IL6 on proliferation were minimal, peaking at 3.125ng/mL and
declining significantly thereafter although remaining marginally significant (fig. 3.6b).
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Figure 3.6a-b
Luteolin attenuates IL-6 induced proliferation in neuroblastoma cells. Measurement of
fluorescent intensity, from labeled nucleic acid residues indicated that mIL6 treatment
significantly increased proliferation in undifferentiated n2a cells, with fluorescent intensity
doubling at 1.625ng/mL (p0.0002), and peaking at 12.5ng/mL (p0.0003) (a). In
differentiated cells, the increase in proliferation was much lower albeit significant peaking
at 3.125ng/mL (p0.009) and drastically declining thereafter. Proliferation at 100ng/mL
was not significant (b). (* p<0.05, **p<0.01, ***p<0.001)
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3.2.5

Effects of IL-6 in neural stem cells may reflect in vivo pathological
consequences of prenatal infection.
The development of the CNS has been shown to be largely dependent on a

series of tightly regulated events including periods of proliferation and targeted
apoptosis.

Although neuroblastoma cells are often utilized as an in vitro model to

examine CNS pathologies the proliferative capabilities of IL-6 and the therapeutic
efficacy of luteolin was further examined in neural stem cells isolated from embryonic
mouse cortices, to closer approximate the in vivo environment.

Interestingly, the

proliferative effects of mIL-6 observed in undifferentiated and differentiated Neuro-2a
cells, were not replicated in neural stem cell (NSC) cultures although significant
proliferation was still observed (fig. 3.7a). This difference may be attributable to the
tumorigenic nature of Neuro-2a cells which has been shown to exhibit significant
proliferative potential and their ability to proliferate independent of exogenous growth
factors primarily through the autocrine expression of transforming growth factors (van
Zoelen et al., 1984). When cells were co-treated with luteolin there was no significant
inhibition of proliferation observed, as levels were comparable and potentially slightly
increased to that observed in IL-6 and even control cells (fig. 3.7b).
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b

Figure 3.7a-b
Effects of IL-6 in neural stem cells may reflect in vivo pathological consequences of
prenatal infection. In NSC cultures, (a) mIL6 treatment resulted in a significant increase
in proliferation at concentrations 12.5ng/mL – 50ng/mL. (b) Luteolin treatment did not
significant attenuate IL6 induced proliferation in NSC. In fact there was a trend toward
an increase in proliferation with all concentrations except 3.125uM and 50uM, which
showed a trend toward a decrease. (*=p<0.05)
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To further investigate this observation, the effects of luteolin were compared in
the presence and absence of IL-6 treatment. As initially eluded to in the experiment
represented in figure 3.8b, the effects of luteolin were influenced by the presence of IL-6.
In the absence of IL-6, luteolin co-treatment attenuated proliferation at higher
concentrations. When IL-6 was present, the effects of luteolin were highly variable. This
effect may be attributed by the presence of growth factors such as epidermal growth
factor (EGF), which maintains stem cells in a proliferative state, and signals through
activation of Stat3.

Stat3 has also been shown to regulated by the interactions of

multiple signaling pathways that converge at Stat3 such as the Erk pathway. Although
luteolin has been shown to modulate Erk, the combined actions of IL-6 and EGF may
impact the therapeutic effects of luteolin on inhibiting IL-6 mediated pathologies.
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Figure 3.8
The ability of luteolin to attenuate IL-6 mediated pathologies modulated by the presence
of growth factors (EGF and FGF). The proliferative effects of IL-6 in neural stem cells
are also affected by the presence of growth factors.
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As the proliferative effects of IL-6 and the modulatory effects of luteolin in NSC
cultures were somewhat unexpected, proliferation was next assessed optically, using
fluorescent microscopy. Characteristically, neural stem cells form spherical structures in
suspension known as neurospheres when maintained in proliferative media,
supplemented with the appropriate growth factors, described previously in chapter 2,
section 2.1. The effects of IL6 and luteolin co-treatment on neurosphere morphology
and number were examined using FITC labeling of cellular nucleic acid, to confirm
previous results. Interestingly there again appeared to be no significant proliferative
effects as there was no significant difference in the total amount of neurospheres or the
size of neurospheres under the different treatment conditions. There was however a
trend towards a difference in neurosphere size following mIL-6 treatment, with an
increase in medium and small neurosphere populations and a corresponding decrease
in the large neurosphere population.

Although not significant, these effects were

reversed by luteolin co-treatment (fig3.9).
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Figure 3.9
IL-6 and Luteolin does not alter neurosphere size or number. Neurospheres were
classified as small (less than 100um), medium (101-200um) or large (greater than
201um). There were no significant changes in the total population of neurospheres
induced by treatment. There were however changes in neurosphere size following mIL6
treatment, with medium sized (101 – 200um) neurosphere populations increasing.
Similarly, luteolin co-treatment did not show significant modulation of IL6 activity
although the increase in the number of medium neurosphere population was reversed.
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3.2.6

Luteolin attenuates IL-6 mediated morphological changes in neural stem
cells
The morphological effects of IL6 and luteolin co-treatment were examined next.

IL6 treatment induced observable changes in neurosphere morphology; specifically
there was a shift from a stem cell phenotype to a commitment to terminal differentiation
evidenced by increased branching and attachment to the culture surface, which was
significantly inhibited by luteolin co-treatment (fig3.10). This effect was not evident in all
neurosphere clones as IL6 seemed to maintain a consistent population of neurospheres
while simultaneously inducing differentiation in others. To further examine this effect
cultures were treated with IL6 in the absence of growth factors.

In these cultures,

neurosphere morphology was maintained at levels comparable to that of control
suggesting that IL6 can maintain neural stem cells in a self-renewal phase characterized
by continuous proliferation or shift them toward lineage commitment and differentiation.
These effects appear to be highly dependent on the immediate microenvironment as can
be seen from the outcomes of this experiment and the observations of proliferation in
differentiated and undifferentiated N2a cells (fig. 3.6).
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Figure 3.10
Luteolin attenuates IL-6 mediated morphological changes in neural stem cells. IL6
treatment (GF/IL6) resulted in increased attachment of cells to the culture surface and
increased branching and dissociation of neurospheres. This effect was attenuated by
luteolin co-treatment (GF/IL6-Lt). In the absence of growth factors, cells fail to maintain
active proliferation, resulting in significant decreases in neurosphere numbers (Control).
IL6 treatment, in the absence of growth factors was able to maintain neurosphere
morphology and active proliferation (IL6), an effect also attenuated by luteolin cotreatment.
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3.2.7

Luteolin attenuates IL-6 mediated differentiation of GFAP positive cells
To confirm that mIL-6 had induced differentiation and lineage commitment, cells

were fluorescently labeled with neuronal and glial specific cellular markers. When IL-6
treated cultures were examined there was in fact increased differentiation and lineage
commitment evidenced by increased expression of neuronal and glial markers Betatubulin and GFAP respectively. Surprisingly, there was no corresponding decrease in
vimentin expression, a marker of neural stem cells, further suggesting the ability of IL6 to
maintain some cells in an uncommitted fate (fig3.11). When cells were co-treated with
luteolin there was a significant decrease in GFAP expression however, this effect was
not seen with Beta-tubulin although there was a trend toward a decrease.
Since GFAP expression has been shown to be a Stat3 dependent event, the
selective attenuation of GFAP expression suggests luteolin effects may be mediated
through modulation of Stat3 signaling.

Additionally, the limited effects on neuronal

populations further confirm, a Stat3 dependent mechanism as well as suggest that the
effects on neuronal populations may be secondary. This secondary effect shows an
indirect mechanism by which the function of neuronal populations are altered by the
actions of astroglial cell populations, as these cells have been shown to be supportive to
neuronal cells cooperating in synaptic transmission as well as providing metabolic
support through the supply of neuroactive molecules.
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Figure 3.11
Luteolin attenuates IL-6 induced GFAP expression in neural stem cells. Following
treatment, cells were triple labeled with anti-GFAP, anti-btub and anti-vimentin and
lineage determined and quantified using confocal microscopy and analytical software.
IL6 treatment (GF/IL6) resulted in a significant increase GFAP (***p<0.0002) and btub
(***p<0.0001) expression although vimentin expression remained constant. GFAP
expression was attenuated by luteolin co-treatment (GF/IL6-Lt) (***p<0.0005) however
there was no significant effect observed with btub expression although there was a trend
toward a decrease.
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3.2.8

IL6 and luteolin activity influenced by extrinsic conditions in the cellular
microenvironment
To further examine the effects of IL-6 and luteolin on lineage specification, IL6

and luteolin co-treatment was examined in differentiated cells already committed to a
specific cellular lineage. When NSC cells, three days post differentiation were treated
with IL6, there were no significant changes observed in GFAP and Beta-tubulin
expression although both populations showed a trend toward an increase. Interestingly,
nestin expression, a marker of uncommitted neural stem cells, was also increased
suggesting an increase in this population of cells. There were also observable changes
in neuronal morphology, specifically increased and less ordered axonal branching. This
effect did not appear to be significantly attenuated by luteolin co-treatment.
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Figure 3.12
IL-6 and Luteolin activity dependent on extrinsic factors in the cellular microenvironment.
Neural stem cells 3 days post differentiation did not show significant changes following
treatment although there was a trend toward an increase in Beta-tubulin and GFAP
expression. This trend was not attenuated by luteolin, as co-treated cultures appeared
to show slight increases although not significant.
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3.3

Conclusions
Prenatal infection and the ensuing increase in maternal cytokines, has been

regarded as a key etiological factor in the pathogenesis of neurodevelopmental
disorders such as ASD.

IL6, already described as a key mediator in inflammatory

disorders, and an important immune regulator, has been cited as being critical to the
adverse outcomes following prenatal infection, as increases in this cytokine have been
strongly correlated to disease pathology, pathologies which have been ameliorated by
following IL-6 inhibition. Additionally, inhibition of this cytokine during prenatal infection
has been shown to attenuate pathological outcomes. In this chapter, the efficacy of
flavonoids such as luteolin in reducing IL-6 mediated pathologies was examined in NSC,
an in vitro model of the effects of prenatal infection on the fetal CNS. Luteolin coadministration was able to attenuate the pathological effects of IL6 particularly increases
in proliferation and excess glial cell expression. Targeted luteolin attenuation of glial cell
commitment, a Stat3 dependent event, and its attenuation of Stat3 phosphorylation
suggest that the neuropathologies were mediated through IL6-Stat3 activation and that
the inhibition of this pathway may be therapeutically beneficial.
A somewhat unexpected but noteworthy observation was the dependence of
mIL-6 activity on cell extrinsic and intrinsic factors, as the pathologies observed in
undifferentiated cells were significantly different than those seen in differentiated cells.
These observations support epidemiological findings that suggest that there is an ‘ideal
window’ where the effects of prenatal infection are more deleterious. In the in vitro
model utilized in this chapter, the effects of IL-6 seemed most significant in
undifferentiated stem cells which suggest that early infections may be most detrimental
to CNS development.

Several studies have emphasized these findings in vivo

suggesting earlier infections provide an ideal opportunity for disruption of key processes
such as cellular proliferation and differentiation. These disruptions precipitate further
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pathologies including alterations in cellular migration and synapse development which
manifest clinically in the neurological and behavioral abnormalities observed in disorders
such as ASD and schizophrenia which have been correlated with prenatal infection
(Meyer et al., 2007). Dopaminergic neurons for example have been shown to emerge
during the early phases of neurodevelopment from precursor populations both in murine
animals and in humans (Bayer et al., 1995, Brana et al., 1996, Marti et al., 2002).
Prenatal infection and resultant maternal and/or fetal cytokine expression during this
period can lead to disruptions in the proliferation, differentiation, migration of these cells
and subsequent disruptions in dopaminergic cellular populations (Brown et al., 2004). It
is plausible that these neuropathologies induced by prenatal infection may account for
the behavioral and neurological abnormalities observed in disorders such as
schizophrenia where disruptions in the dopaminergic system have been a consistent
finding. These findings however do not preclude the ability of prenatal infection during
late gestation to induce adverse pathological outcomes. Indeed infections during this
developmental window have been shown to induce disruptions in cellular migration,
neuronal organization, and synaptogenesis (Buka et al., 2001, Gilmore et al., 2004).
It is evident that infections during pregnancy have to potential to lead to adverse
neurological outcomes in exposed offspring and the timing of infection may impact the
nature of pathologies observed clinically.

Early infections allow for opportunities to

disrupt proliferation, differentiation and migration of cellular populations that can lead to
multiple morphological, structural and functional abnormalities due to the potential to
impact multiple cellular populations.

By contrast, later infections may have more

targeted effects, producing disruptions to the positioning and interactions of specific
cellular populations that may be vulnerable due to migration, synapse formation (Buka et
al., 2001, Meyer et al., 2007). The implications of these divergent outcomes can be
seen in the nature of the pathologies attributed to earlier infections, where
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symptomology is often more heterogeneous as can be seen in disorder such as ASD
and schizophrenia. By contrast, later infections may give rise to certain cognitive deficits
and similar neurological abnormalities.
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CHAPTER 4
FLAVONOIDS, A PRENATAL PROPHYLAXIS FOR ADVERSE PERINATAL
OUTCOMES AFTER PRENATAL INFECTION

4.1

Prenatal infection, Cytokines and the Placental Barrier
The pleiotropic nature of cytokines, particularly their involvement in both

pathological and physiological events and their ubiquitous expression throughout the
body and at various developmental periods make them prime targets as mediators of the
adverse outcomes resulting from prenatal infection. Despite evidence of their function in
this capacity however, there is still disagreement as to their role in neurodevelopmental
and/or neuropsychiatric disorders such as ASD (Dassa et al., 1995, Chen et al., 2004).
Adding to this disagreement has been a lack of consensus as to whether or not maternal
cytokines, produced during prenatal infection, can traverse the placental barrier and
disrupt fetal development. Research focusing on the placental migration of cytokines,
following prenatal infection has yielded contradictory results with some studies reporting
a positive results while others have reported no migration (Bell et al., 2004, Aaltonen et
al., 2005, Ashdown et al., 2006). These contradictions may be attributed to variations in
experimental design as comparative studies have shown that the ability of maternal
cytokines to traverse the placental barrier may be highly dependent on the time of
immune challenge. IL-6 for example has been shown to traverse the rat placenta during
mid-gestation, approximately embryonic days 11–13, while this observation is not seen
during embryonic days 17–19 (Bell et al., 2004, Dahlgren et al., 2006).
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It is worthwhile to note, that even with no observable cytokine migration during
late gestation, prenatal infection during this period has still been shown to increase
cytokine levels in the fetal CNS, and precipitate adverse neurological outcomes.
Additionally, murine models of prenatal infection utilizing LPS, which does not traverse
the placental barrier, have induced both maternal and fetal inflammatory responses
following prenatal administration (Bell et al., 2004, Elovitz et al., 2011). These findings
suggest that instances of prenatal infection not only activate the maternal immune
system, but can propagate a cascade of inflammatory responses inducing inflammation
in the placenta as well as the fetal CNS. This can in turn lead to adverse changes in
placental function and the development and function of the fetal CNS.

4.1.1

Current animal models of adverse perinatal outcomes following prenatal
infection
Although the mechanism by which maternal cytokines disrupt fetal CNS

development is not fully understood, findings from animal models have highlighted their
role in the pathological changes that may precipitate later neuroanatomical,
immunological and behavioral abnormalities in prenatally exposed offspring. In murine
models of prenatal influenza exposure, neuropathologies including changes in cell
density, cell atrophy and neurochemical abnormalities such as disruptions in serotonin
levels were observed. These pathologies mirror clinical findings in disorders such as
schizophrenia and ASD, and may explain the alterations in the levels of
neurotransmitters such as serotonin and its metabolites observed in these disorders
(Fatemi et al., 2002, Meyer et al., 2008, Winter et al., 2008). Behavioral correlates
among prenatally exposed murine offspring have also been observed.

Particularly

deficits in prepulse inhibition in adult offspring following prenatal exposure to bacterial
endotoxin LPS or synthetic viral analog polyinosinic:polycytidylic acid (poly(I:C)) have
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been observed, a pathology representative of deficits in sensorimotor gating, an inability
to filter out extraneous information, and a well-known pathological feature in disorders
such as ASD and schizophrenia (Fortier et al., 2007).
In addition to neurodevelopmental abnormalities, these models have also shown
instances of pregnancy disorders including preeclampsia and spontaneous recurrent
miscarriages that seem to result from disruptions in maternal immunity (Makhseed et al.,
2000, Laresgoiti-Servitje et al., 2010, Tosun et al., 2010, Holder et al., 2011, Jin et al.,
2011). These disorders have described observations of aberrant T cell differentiation
with uncharacteristic increases in cytotoxic T cell populations, an IL-6 influenced event,
and reductions in immune suppressant T cell populations (Kimura and Kishimoto, 2010,
Fujimoto et al., 2011). This scenario contrast observations in normal pregnancies where
increases in the number of immunosuppressive T-regs preceding and after implantation
of the fetus, prevent the proliferation and activation of cytotoxic Th17 cells ensuring the
ability to maintain a viable pregnancy (Aluvihare et al., 2004, Heikkinen et al., 2004,
McCracken et al., 2004, Somerset et al., 2004, Hunt et al., 2005, Zenclussen et al.,
2006, Kallikourdis et al., 2007, Kallikourdis and Betz, 2007, Kahn and Baltimore, 2010,
Dimova et al., 2011). IL6 has therefore been shown to be a recurrent pathological
feature and potential site of intervention in disorders precipitated by prenatal infection.

4.1.3

Luteolin as a therapeutic intervention – potential mechanism
As the inhibition of IL-6 and its mediated activation of Stat3 are known to reduce

pathological outcomes following prenatal infection, prenatal flavonoid treatment may
prove to be of therapeutic value for both maternal and fetal pathologies. Several studies
have shown that flavonoids are potent anti-inflammatory agents that act through
modulation of tyrosine kinase activity to inhibit cytokine production, and the expression
of other pro-inflammatory mediators.

This has been confirmed in studies involving
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stimulation of immune cells with flavonoids such as luteolin resulting in a reduction in the
expression of cytokines such as IL6 and Tumor necrosis factor-alpha (TNF-α), with
inhibition of Stat3, nuclear factor kappa light chain enhancer of activated B cells (NF-κB)
and Protein Kinase B (Akt) being implicated as potential mechanisms (Hirano et al.,
2006, Jang et al., 2008, Zhu et al., 2011).

4.2

Results

4.2.1

Luteolin attenuates maternal immune response following prenatal infection
Activation of the maternal immune system following prenatal infection,

particularly the release of maternal cytokines has been cited as the major contributor to
adverse perinatal outcomes. Particularly, disruptions in cytokine expression and T-cell
differentiation have been cited as key mediators in adverse perinatal events through
their disruption of placental function. The spleen is an important immune organ and
source of pro-inflammatory cytokines. During prenatal infection, the spleen has been
shown to be an important mediator of the maternal inflammatory response and cytokine
expression (Athanassakis and Iconomidou, 1996).

Here, splenocytes isolated from

female C57BL/6 mice were challenged with lipopolysaccharide (LPS) or concavalin A
(conA) and co-treated with luteolin to examine attenuation of inflammatory responses
and splenic cytokine expression. LPS is a bacterial endotoxin utilized in animal models
to elicit immune reactions including pro-inflammatory cytokine production, while. conA is
often utilized as a T-cell mitogen. When LPS challenged splenocyte cultures were cotreated with luteolin, there was a significant inhibition of IL-6 and TNF-α expression.
Similarly, in cultures challenged with conA, luteolin co-treatment also significantly
inhibited IL-6 and TNF- α expression.
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a

b

Figure 4.1a-b
Luteolin attenuates pro-inflammatory cytokine expression from LPS or conA challenged
splenocytes. Elisa cytokine analysis showed luteolin co-treatment significantly inhibits
LPS mediated IL6 (a) and TNF-α (b) expression from splenocyte cultures in a
concentration dependent manner (***p<0.001).
These results represent five
independent experiments.
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a

***

b

Figure 4.1c-d
Elisa cytokine analysis showed luteolin co-treatment significantly inhibits LPS mediated
IL6 (c) and TNF-α (d) expression from splenocyte cultures in a concentration dependent
manner (***p<0.001). These results represent five independent experiments.
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To further confirm the efficacy of flavonoids such as luteolin in attenuating
maternal immune activation during prenatal infection, cytokine production was further
examined in the spleens of recently delivered prenatally infected mice. As IL-6 mediated
activation of Stat3 have been shown to play a critical role in immune regulation,
particularly in the propagation of inflammatory responses, including the differentiation of
cytotoxic or pro-inflammatory T-cell populations, and pro-inflammatory cytokine
expression following infection, the role of Stat3 in mediating this inflammation, and the
ability of luteolin to attenuate Stat3 activation was also examined. Pregnant mice were
treated with 5 µg/mL mIL-6, 50ug/kg LPS, or co-treated with these compounds in the
presence of 10mg/kg luteolin at embryonic day 12 (E12). Mice injected prenatally with
LPS and IL6 showed significant increases in TNF-α and interleukin1- β (IL1-β)
expression which was attenuated by luteolin co-treatment.
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a

b

Figure 4.2a-b
Luteolin attenuates maternal immune responses following prenatal infection. Luteolin
co-treatment significantly inhibited cytokine production in spleens from mice prenatally
injected with LPS or IL-6. Luteolin alone also significantly reduced cytokine expression
below that of control levels (***p<0.001).
Stat3 has also been shown to play a major role in the progression of
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inflammatory processes following infection.

Additionally, IL-6 mediated activation of

Stat3 has been implicated as key in the differentiation of cytotoxic T-cell populations
from naïve T-cells. Stat3 activity was analyzed and the effect of luteolin co-treatment
was assessed in spleens isolated from prenatally treated mice.

In mice treated

prenatally with LPS, there was a significant increase in Stat3 phosphorylation confirming,
its involvement in potentiating inflammatory responses.

When luteolin was co-

administered with LPS, Stat3 phosphorylation was significantly reduced, to levels
comparable to that of control animals.
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Figure 4.3
Luteolin attenuates Stat3 phosphorylation in maternal spleens following prenatally
infection. Luteolin co-treatment significantly inhibited Stat3 phosphorylation in spleens
from mice prenatally injected with LPS or IL6 (**p<0.05).
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4.2.2

Luteolin attenuates adverse fetal outcomes following prenatal infection
Several adverse perinatal events including premature delivery, in utero growth

restriction, and often more serious outcomes such as neurological disorders, recurrent
miscarriages and preeclampsia have been attributed to prenatal infection. Attenuation of
the maternal immune response to infection may serve as a therapeutic alternative not
only for developmental outcomes but also for adverse pregnancy outcomes. In mice
exposed prenatally to LPS or IL-6 at E12, there was a significant decrease in the birth
weight of offspring suggestive of in utero growth restriction. This effect was attenuated
by luteolin co-treatment. An unexpected result of luteolin treatment was an apparent
increase in birth weight. There were no visible abnormalities observed after treatments.
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Table 4.1
Luteolin attenuates adverse fetal outcomes following prenatal infection.
Treatment

Ctl/PBS

LPS

IL6

LPS/Lt

IL6/Lt

Average litter weight 1.33±0.10 1.27±0.13* 1.25±0.09* 1.35±0.13* 1.36±0.13*

Figure 4.4
Luteolin attenuates adverse fetal outcomes following prenatal infection. Offspring
exposed prenatally to IL6 showed an average decrease in birth weight when compared
to their non-exposed counterparts (*p<0.05). This was attenuated by luteolin, although
there was an increase in birth weight associated with luteolin treatment (*p<0.05). There
were no observable physical abnormalities observed.
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4.2.3

Diosmin reduced pro-inflammatory cytokine production and Jak2/Stat3
phosphorylation in the brain tissues of IL-6 newborn mice
To further expand on the efficacy of flavonoid treatment during instances of

prenatal infection, an in vivo model of dietary intervention was utilized. For the following
experiments, pregnant mice were treated with 5ug/mL mIL-6 in the presence or absence
of diosmin (10 mg/kg/day diosmin) administered orally in their chow from E12 until birth.
As a positive control, a subgroup of mice were co-treated with IL-6 and Stat3 inhibitor
S31-201 (4ug/mL) at embryonic day 12 (E12).

Cytokine production and Jak2/Stat3

phosphorylation was examined in the brain homogenates of new born mice. In mice
prenatally exposed to IL-6, there was a significant increase in pro-inflammatory
cytokines TNF-α and IL-1β levels compared to controls.

These increases were

significantly reduced by almost 50% in the presence of S31-201 or diosmin. Western
blot analysis of brain homogenates show that both S31-201 and diosmin significantly
reduce IL-6 induced Jak2 and Stat3 phosphorylation.
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Figure 4.5
Diosmin reduced pro-inflammatory cytokine production in the brain homogenates of
prenatally exposed newborn mice. Pro-inflammatory cytokine analysis by ELISA was
conducted on these newborn mouse brain homogenates. Analysis of results revealed a
significant reduction of TNF-α and IL-1β cytokines in brain homogenates from IL-6/S31201 and IL-6/Diosmin/newborn mice when compared to IL-6 only (MIA model) newborn
mice (**P < 0.01).
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Figure 4.6
Diosmin reduced Jak2/Stat3 phosphorylation in the brain homogenates of prenatally
exposed newborn mice. Brain homogenates were prepared from newborn mice from
mothers injected with IL-6, IL-6/S31-201, IL-6/diosmin or PBS (control). Treatment of
S31-201 or diosmin significantly inhibited IL-6-induced Jak2/Stat3 phosphorylation in
brain tissues from newborn mice. Densitometry analysis shows the ratio of phosphoJak2/Stat3 to total Jak2/Stat3 as indicate below the figures. One-way ANOVA showed
that both significantly inhibit Jak2/Stat3 signaling (P <0.005).
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4.2.4

Prenatal diosmin co-treatment reduces abnormal behaviors in offspring
following prenatal infection through inhibition of Stat3 pathway
Abnormal social behaviors, and in some instances anxiety are prominent

features in disorders such as ASD and schizophrenia. To further examine the efficacy of
flavonoid dietary intervention in attenuating the pathological effects of prenatal infection,
the behavior of adult offspring exposed prenatally to IL-6 and flavonoid intervention was
examined.

The open field test was used to assess general locomotor activity and

anxiety while the social interaction test was used to assess social behaviors. Pregnant
mice were treated as described in the previous section and their adult offspring
examined for behavioral outcomes.

In mice exposed prenatally to IL-6, there were

significant behavioral disruptions observed. In the open field test, these mice spent less
time in the inner section compared to control, S31-201 or diosmin treated mice.
Offspring of mice co-treated with either S31-201 or diosmin showed behaviors
comparable to that of control mice. The open field test measures anxiety as a function
of entries the test animal makes into an arbitrarily defined ‘center’. Since this measure is
highly dependent on the total distance travelled within the apparatus, changes in
locomotor activity in one group could significantly skew the outcome measures. To
account for this, ANOVA on distance traveled in the inner section was performed and did
not indicate a main effect. Analyses of distance traveled in the outer section did not
reveal a significant difference or a statistical trend towards a significant difference among
groups. There was not a significant difference between PBS-treated mice and S31treated control (non-IL-6 injected) mice.
In the social interaction test, the adult offspring of control mice showed a strong
preference for the social chamber, almost double that of the adult offspring of IL-6
treated mice confirming impairments in social behaviors in mice exposed prenatally to
IL-6. This social impairment was significantly reduced by maternal co- treatment with
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S31-201 or diosmin as these mice showed a preference for the social chamber
comparable to that of control adult offspring. To quantify social interaction, exploration
demonstrated as sniffing time was analyzed via ANOVA. There was a main effect of
group; the S31-201 or diosmin mice exhibited an increase in sniffing compared to IL6/MIA mice. There were no observations of social grooming, chasing, dominant mounts,
pinning, boxing, or biting. There were no significant differences in total move time and
total distance traveled.
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Fig. 4.7
Maternally blocking Stat3 activity reduces abnormal behaviors in prenatally exposed
animals. Offspring of mice (n = 8, 4 female/4 male) intraperitoneally (i.p.) treated with IL6 (5 µg/mouse) in the absence or presence of STAT3 inhibitor (S31-201; 4 µg/mouse;
i.p.) (Siddiquee et al., 2007) or with diosmin [oral administration; (10 mg/kg/day)]. (a) In
the open-field test, offspring of mice treated with either S31-201 or diosmin enter the
center more often than IL-6 (**P < 0.01) and are nearly similar to control mice. (b) In the
social interaction test, as previously reported, the social chamber was defined as
(percentage of time in social chamber) – (percentage of time in opposite chamber).
Most notably, control mice reveal a strong preference for the social chamber.
Interestingly, the social impairment of offspring is significantly improved by maternal
administration of STAT3 inhibitor, S31-201 or diosmin (**P < 0.005).
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4.2.5

Diosmin reduces pro-inflammatory cytokines and Stat3 phosphorylation in
prenatally exposed animals
After behavioral testing, adult offspring were sacrificed to confirm that inhibition of

Stat3

phosphorylation

by

diosmin

attenuates

IL-6/Stat3

induced

behavioral

abnormalities. At sacrifice, brain homogenates were prepared from control mice and
mice exposed prenatally to IL-6, IL-6/S31-201, and IL-6/Diosmin.

Pro-inflammatory

cytokine ELISA showed significant increases in TNF-α and IL-1β levels in the
homogenates of IL-6 adult offspring. Maternal co-treatment with S31-201 or diosmin
significantly reduced TNF-α and IL-1β cytokine levels, with diosmin showing slightly
more significant reductions as shown in Fig. 4.8.
Western blot analysis of phospho- and total Stat3 showed that prenatal IL-6
treatment increased Stat3 phosphorylation in the brain homogenates of adult offspring
while co-treatment with either S31-201 or diosmin lead to a significant reduction of
STAT3 phosphorylation. This data suggest that activation of the Stat3 pathway following
prenatal infection is a plays a major role in the resultant pathologies including behavioral
deficits. Inhibition of Stat3 activation, by diosmin reduces these behavioral deficits and
may be a key therapeutic intervention strategy.
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Fig. 4.8
Diosmin reduces pro-inflammatory cytokine expression in the brain homogenates of
prenatally exposed animals. Pro-inflammatory cytokine analysis by ELISA revealed a
significant reduction of TNFα and IL-1β cytokines in brain homogenates from IL-6/31201 and IL-6/Diosmin adult offspring when compared to offspring prenatally exposed to
IL-6 only.(**P < 0.05).
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Fig. 4.9
Diosmin attenuates Stat3 phosphorylation in the brain homogenates of prenatally
exposed animals. Western blot analysis showed a significant reduction of STAT3
phosphorylation in brain homogenates from IL-6/S31-201 and IL-6/Diosmin/adult
offspring when compared to offspring of IL-6 offspring. These reductions were further
showed by densitometric analysis (**P < 0.005).

70

4.3

Discussion
Epidemiological

data,

clinical

findings

from

pregnancy

disorders

and

observations from murine models of prenatal infection have supported a role for
activation of the maternal immune system, and subsequent maternal cytokine
expression as a key component of their pathological mechanism (Hwang and Chen,
Brown et al., 2000, Brown and Susser, 2002, Li et al., 2009, Atladottir et al., 2010).
Furthermore, IL-6 has been shown to be an important mediator of these pathological
events through its dysregulation of the Stat3 pathway.

This chapter shows how

flavonoids luteolin and diosmin not only attenuate IL-6 mediated Stat3 activity but more
importantly the adverse maternal and fetal outcomes stemming from prenatal infection.
To confirm the ability of luteolin to attenuate maternal immune responses during
prenatal infection, cytokine production from the spleen was examined following an
immunological challenge. The spleen is an important mediator during immune activation
and a reservoir of pro-inflammatory cytokines. In splenocytes challenged with LPS or
conA luteolin co-treatment significantly inhibited IL-6 and TNF-α expression.
Immunological disruption including increased IL-6 expression has been shown to be a
consistent feature in adverse perinatal outcomes precipitated by prenatal bacterial or
viral infections or instances of chronic immunological dysregulation. Increased plasma
levels of IL-6 for example has been observed in FIRS precipitated by bacterial infections
as well as in preeclampsia, thought to be connected to immunological disruptions
(Gomez et al., 1998, Chaiworapongsa et al., 2002, Tosun et al., 2010, Zhou et al.,
2011). The ability of luteolin to inhibit inflammatory response to both LPS and conA
suggest it may be a key therapeutic alternative in a wide range of pregnancy disorders
as these two mitogens elicit immune reactions through very different mechanisms.
These findings were also confirmed by in vivo analysis. When spleens isolated
from recently delivered mice challenged with LPS or IL-6 were analyzed, TNF-α and IL71

1β, were reduced by luteolin in co-treatment. TNF-α and IL-1β have both been shown to
indirectly induce IL-6 expression and Stat3 activity (Mori et al., 2011). As increased
Stat3 activity is a known consequence of IL-6 expression, this was also examined. Stat3
phosphorylation was significantly reduction by luteolin co-treatment in prenatally
challenged animals.

The attenuation of maternal immunological disruptions and

cytokine expression by luteolin also reduced fetal pathological outcomes, particularly
growth restrictions, as mice exposed prenatally to LPS or IL-6 had significantly lower
birth weights than control offspring, a pathology not seen in the offspring of mice that
received luteolin co-treatment.
It is clear that maternal immunological disruptions following prenatal infection
play an important role in adverse perinatal outcomes, however fetal immunological
responses have also been observed to play an equally important role in pathologies,
particularly the neurological abnormalities observed in prenatally exposed offspring
(Dammann and Leviton, 2000, Chaiworapongsa et al., 2002). To examine the ability of
flavonoids to attenuate fetal immune responses, fetal cytokine expression and Stat3
activity were examined in newborn and adult offspring, while abnormal behaviors were
analyzed in the adult offspring of prenatally exposed animals.

A more chronic

administration route of flavonoid treatment was also examined.

Diosmin dietary

intervention was utilized to examine prenatal supplementation of flavonoids and their
effects on fetal outcomes.

Similar to maternal outcomes, there was an increase in

inflammatory cytokines and Stat3 phosphorylation in the brains of prenatally exposed
animals which was attenuated by diosmin co-treatment. Additionally, behavioral deficits
observed in these animals were also attenuated following diosmin co-treatment. It is
therefore evident that flavonoid co-treatment is a beneficial therapeutic intervention in
prenatal infection, as it can reduce the neuropathological and abnormal behavioral
outcomes seen in prenatally exposed offspring.
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CHAPTER 5
CONCLUSION

Clinical observations in disorders such as preeclampsia, schizophrenia and ASD
have highlighted the role of maternal immune activation and subsequent IL-6
expression, often a consequence of prenatal infection, in the pathological features
observed in these disorders. Similarly, murine models replicating these disorders have
identified this immune reaction and IL-6 expression as a central component of the
pathological mechanism.

Studies have also shown that IL-6 may be a measurable

indicator of pathology and target of therapeutic intervention as inhibition of IL6 has been
shown to reduce associated disease pathology (Smith et al., 2007, Zhou et al., 2011). In
disorders such as preeclampsia for example, elevations in IL-6 have been implicated as
an observable and measurable mediator of hypertension through its regulation of
vasoconstrictive proteins and its inhibition has been shown to reduce this pathology
(Zhou et al., 2011).

Similarly, in models of prenatal infection meant to recapitulate

neurodevelopmental disorders such as ASD, IL-6 has been shown to induce not only the
neuropathologies such as abnormal cellular morphology, but also abnormal behaviors
such as impaired social interactions, outcomes all attenuated by inhibition of IL-6 (Smith
et al., 2007).
This study further explores how prenatal infection can lead to adverse perinatal
outcomes, particularly changes in neuroanatomy that seem to precipitate the abnormal
behavioral outcomes observed in prenatally exposed offspring and clinically in disorders
such as ASD. More specifically, it focuses on role of IL-6 mediated activation of the

73

Stat3 pathway in these pathologies and how attenuation of this pathway, by flavonoids
can reduce the pathological outcomes associated with prenatal infection. Chapter three
explores this relationship by utilizing an in vitro model of pathological IL-6 expression to
examine the neuropathologies that may occur following prenatal infection and
subsequent exposure to IL-6.

Treatment of neural stem cells with IL-6 revealed

significant pathologies including increases in proliferation, and aberrant patterns of
differentiation.

Most notably, and possibly most relevant to clinical observations in

disorders such as ASD were findings of increased astroglial differentiation following IL-6
treatment, an effect inhibited by luteolin co-treatment. Astrocyte pathologies have been
implicated in neurological disorders such as epilepsy due largely to their role in
regulating synaptic transmission, and their supportive role in maintaining optimal
neuronal function and integrity in the CNS (Brunello et al., 2000, Dutuit et al., 2000,
Brenner et al., 2001).

These types of pathologies may be particularly relevant in

disorder such as ASD as increased expression of astroglial markers such as GFAP and
aquaporin 4 have been observed in post mortem autistic brain samples (Fatemi et al.,
2004, Laurence and Fatemi, 2005, Fatemi et al., 2008a). When NSC cultures were cotreated with IL-6 and luteolin, astroglial differentiation, a Stat3 mediated event was
significantly reduced. An examination of Stat3 phosphorylation showed that this was
also significantly reduced following luteolin co-treatment suggesting prenatal luteolin
treatment has the potential to attenuate IL-6/Stat3 mediated pathologies.
To expand on these findings, luteolin’s effects were investigated in vivo. The
effects of chronic prenatal administration were also examined using diosmin.

The

experiments outlined in chapter four looked at the ability of luteolin and diosmin to inhibit
activation of the maternal immune system as well as adverse fetal outcomes such as low
birth weight, indicative of in utero growth restriction and abnormal behaviors. To look at
maternal immune reactions, luteolin activity was examined in splenocyte cultures as well
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as the spleens of recently delivered prenatally exposed animals. Luteolin treatment was
able to attenuate inflammatory response following prenatal infection, an event mediated
by attenuation of Stat3 phosphorylation, which was also inhibited by luteolin cotreatment. Specifically, luteolin inhibited expression of IL-6 and TNF-α in splenocytes
challenged with LPS or conA, confirming the ability of luteolin to attenuate maternal
immune responses independent of the pathogenic stimuli.

In spleen tissue, luteolin

inhibited TNF-α and IL-1β expression in the spleens of mice challenged with IL-6 or LPS.
Like IL-6, these cytokines have been shown to be elevated following prenatal infection
and during other instances of immune dysregulation and can indirectly induce IL-6
expression and resultant activation of Stat3 (Mori et al., 2011).
The inhibition of maternal immune activation following prenatal infection by
luteolin suggests fetal pathologies resulting from prenatal infection can also be
attenuated by prenatal flavonoid treatment. To confirm this, several fetal outcomes were
examined, including birth weight, as decreased birth weight is a known consequence of
prenatal infection.

As expected, prenatal infection not only activated the maternal

immune system but also led to decreased birth weight in exposed offspring a feature
often correlated to subsequent neurological deficits. These effects were significantly
inhibited by luteolin co-treatment. The neurological consequences of prenatal infection
were examined next. Although maternal cytokine expression has been noted as central
to the pathologies attributed to prenatal infection, fetal immune activation has also been
observed and are considered a key mediator of the neuropathologies and resultant
neurological deficits observed in exposed offspring. Chronic flavonoid administration as
a potential prophylactic intervention was examined next using diosmin dietary
supplementation.

Examination of the brain homogenates of newborn mice exposed

prenatally to IL-6 showed significant increases in TNF-α and IL-1β expression as well as
increased Stat3 phosphorylation. In the offspring of animals maintained on a diosmin
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enriched diet from the time of prenatal challenge until birth, these pathologies were
inhibited. To confirm the role of Stat3 activity in the neurological deficits following prental
infection, behavioral outcomes were examined in prenatally exposed adult offspring.
The efficacy of flavonoids and inhibition of IL-6/Stat3 activity in reducing these abnormal
behavioral outcomes were also examined. In mice prenatally exposed to IL-6, there
were significant behavioral abnormalities observed including deficits in social interaction,
a prominent feature in ASD and schizophrenia. In animals co-treated with diosmin, this
deficit was significantly attenuated. More importantly, analysis of brain homogenates
following behavioral assessment showed an attenuation of pro-inflammatory cytokine
production and Stat3 phosphorylation.
Currently there is no cure for ASD and therapeutic interventions focus primarily
on the management of symptoms, utilizing behavioral therapy to control the abnormal
behaviors and pharmacological intervention to manage comorbid conditions. The role of
prenatal infection in precipitating adverse pregnancy and fetal outcomes has not only
provided a potential mechanism but a focus for therapeutic intervention as targeted
inhibition of IL6 and Stat3 activation has been shown to attenuate, and in many cases
completely ameliorate pathological outcomes.

In addition to neurological disorders

attributed to prenatal infection, disorders of pregnancy such as preeclampsia and
recurrent spontaneous abortions share a similar pathology to those precipitated by
prenatal infection due to the involvement of maternal immune dysregulation.

This

overlap in pathological features suggests that modulation of the maternal immune
system may also be beneficial in these disorders and may be a potential therapeutic
alternative. While some of these disorders such as recurrent miscarriages seem to be
characterized by a persistent dysregulation of the maternal immune system and may
require more aggressive and chronic treatments, others such as preeclampsia often
appear more transient with a sudden onset of pathological symptoms and may benefit
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from short term interventions. The results of this study show the potential for both
chronic and one time flavonoid intervention to yield significant therapeutic effects.
Additionally, the relative safety of many of these flavonoid compounds make their
application during pregnancy for chronic or transient treatment feasible as compounds
such as diosmin have already been shown to be safe when administered during
pregnancy (Buckshee et al., 1997). Although there is room for more research in this
area, the potential application of flavonoid compounds, particularly diosmin and luteolin,
is evident in light of their therapeutic efficacy in attenuating both maternal and fetal
adverse outcomes during periods of maternal immune activation, or dysregulation.
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